Home / Themes / MedTech '25: Neuromodulation & Neurotechnology

MedTech '25: Neuromodulation & Neurotechnology (open on stockthemes)

Last updated

Theme thesis · 4/5 sections · Tickers 2 with notes · 11 pending

Loading chart…
Loading…

Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).

Bull / Bear Details

Neuromodulation companies develop implanted and noninvasive devices that alter electrical activity in the brain, spinal cord, peripheral nerves and autonomic ne

Thesis

Neuromodulation companies develop implanted and noninvasive devices that alter electrical activity in the brain, spinal cord, peripheral nerves and autonomic nervous system to treat neurological, psychiatric, pain-related, respiratory and cardiovascular disorders. The theme captures deep brain stimulation, spinal cord stimulation, responsive epilepsy systems, vagus nerve stimulation, transcranial magnetic stimulation and emerging nerve-interface therapies. Growth depends on expanded clinical indications, improved closed-loop stimulation, reimbursement coverage, greater physician adoption and substitution for medications or invasive treatments that provide inadequate symptom control.

Bull case

  • Closed-loop and responsive stimulation systems improve treatment personalization by measuring neural activity and adjusting electrical output, potentially increasing clinical efficacy and expanding adoption across epilepsy, chronic pain and movement disorders.

  • Broader insurance coverage and improved clinical evidence expand addressable patient populations for drug-resistant depression, epilepsy, sleep apnea and chronic pain, allowing device therapies to compete more effectively with pharmaceutical treatment and conventional care.

  • Miniaturized implants, improved batteries, externally powered stimulators, remote programming and more precise electrode targeting reduce treatment burdens and enable additional therapeutic applications across autonomic and peripheral nerve disorders.

Bear case

  • Neuromodulation procedures carry risks of infection, lead migration, device malfunction, revision surgery and inconsistent patient responses, potentially limiting adoption and increasing postmarket surveillance and liability costs.

  • Reimbursement restrictions, prior authorization requirements, uncertain long-term clinical benefits and competition from pharmaceutical or noninvasive therapies can prevent promising technologies from achieving commercially meaningful procedure volumes.

  • Competitive pricing, increasingly crowded stimulation markets, patent disputes, expensive clinical trials and evolving regulatory standards can compress device economics while delaying commercialization of next-generation closed-loop and experimental neurotechnology platforms.

Overview

Hiring Trend Watchpoints

High-performing neurotechnology companies demonstrate robust job growth in field clinical specialists (FCS) and therapy consultants who provide direct procedural mapping and case coverage in operating rooms and outpatient clinics [Theme_BullBearDetails]. Evidence of theme acceleration includes expanding regional reimbursement access managers and patient prior-authorization specialists, necessary for converting Medicare Advantage policy wins and AMA CPT updates into cash flow [Bull2, Theme_KeyMetrics]. R&D recruitment shifts toward closed-loop embedded firmware, telemetry data engineering, and label-expansion clinical affairs. A thematic warning sign would be hiring freezes or attrition across field clinical teams, restructuring away from direct hospital sales to third-party distributors, or flatlining open requisitions in market access, indicating commercial coverage pushback or hospital capital expenditure freezes [Theme_BullBearDetails].

Forum Watchlist

  • Subreddit — r/TMSHigh

    Patient feedback on therapy effectiveness, clinic access, and commercial insurer prior authorization approvals versus denials for TMS platforms.

  • Physician Forum — Student Doctor Network - Neurology & Psychiatry ForumsHigh

    Physician discussion regarding CPT reimbursement viability, clinic practice economics, and clinical guideline positioning for non-pharmacological interventions.

  • Subreddit — r/epilepsyMedium

    Patient sentiment, physician referral trends, and replacement cycle experiences for responsive neurostimulation and neuromodulation implants.

  • Industry Community — Neurotech Business Report CommunityMedium

    Executive commentary on CMS reimbursement rulings, FDA breakthrough device velocity, and corporate M&A activity.

  • Patient Community — Heart Failure Patient Support CommunitiesLow

    Grassroots patient discussions regarding autonomic neuromodulation implants like Barostim and referral hurdles through cardiology networks.

Industry Publications

  • Neurotech Reports (neurotechreports.com) — Specialized publication providing comprehensive coverage of bioelectronic medicine, neurostimulation clinical trials, venture financing, and regulatory approvals.
  • MedTech Dive (medtechdive.com) — Core industry outlet delivering real-time reporting on FDA breakthrough device designations, CMS Medicare coverage policy changes, and procedural volume trends.
  • Medical Design & Outsourcing (medicaldesignandoutsourcing.com) — Focuses on the engineering, clinical development, and supply-chain dynamics of implantable and non-invasive neurotechnology hardware.
  • Fierce MedTech (fiercebiotech.com/medtech) — Broad coverage of regulatory milestones, strategic medtech M&A, and clinical outcomes across chronic care neurotechnologies.
  • Neuromodulation: Technology at the Neural Interface (sciencedirect.com/journal/neuromodulation) — Official journal of the International Neuromodulation Society publishing peer-reviewed clinical efficacy data, registry studies, and device safety evaluations.

Second Order Trends

First, devices are rapidly transitioning from traditional open-loop continuous stimulation to adaptive, closed-loop bioelectronic architectures that record physiological signals (such as electrocorticography or evoked compound action potentials) and stimulate only on demand. Second, site-of-care migration is accelerating into ambulatory surgical centers (ASCs) and physician office settings, driven by favorable CMS Outpatient Prospective Payment System (OPPS) rules that reward lower-cost care settings over inpatient stays [Bull2, Theme_BullBearDetails]. Third, the implementation of the CMS RAPID pathway aligns FDA breakthrough clearance with expedited 60-to-90 day Medicare coverage determinations, significantly shortening the traditional multi-year reimbursement valley of death. Finally, device makers are increasingly positioning neuromodulation as an autonomic adjunct to cardiometabolic drugs (including GLP-1s) rather than a direct competitor, expanding total addressable procedural markets.

Search Keywords Brand Product

  • Barostim
  • Barostim Neo
  • NeuroStar
  • NeuroStar Advanced Therapy
  • RNS System
  • Deep TMS
  • Senza
  • Evoke System
  • VNS Therapy
  • Ceribell System
  • Nalu Neurostimulation System
  • neuromodulation
  • neurotechnology devices
  • bioelectronic medicine
  • transcranial magnetic stimulation
  • responsive neurostimulation
  • baroreflex activation therapy
  • spinal cord stimulation
  • non-invasive neurostimulation

Search Keywords Policy Regulatory

  • CMS RAPID coverage pathway
  • Breakthrough Devices Program
  • Transitional Coverage for Emerging Technologies
  • Medicare Advantage neuroprocedure coverage
  • OPPS neuromodulation reimbursement
  • Category I CPT code

Search Keywords Event Phrases

  • NANS Annual Meeting
  • North American Neuromodulation Society Annual Meeting
  • American Academy of Neurology Annual Meeting
  • Heart Failure Society of America Scientific Meeting
  • American Epilepsy Society Annual Meeting
  • CMS Annual Physician Fee Schedule Rule

Google Trend Product Category Intent

• TMS therapy near me • TMS therapy cost • Barostim implant • responsive neurostimulation system • vagus nerve stimulator surgery

Google Trend Consumer Intent

• non drug depression treatment • TMS for depression • heart failure device implant • neurostimulation for epilepsy • chronic pain nerve stimulator

Google Trend Macro Policy Terms

• Medicare coverage TMS therapy • FDA breakthrough device • Medicare Advantage neurodevice • bioelectronic medicine

Economic Data Watch

1. U.S. Bureau of Labor Statistics / FRED — Producer Price Index by Industry

Matchedfred · access=api · map_only

Metric/field PCU334510334510 (Electromedical Apparatus Manufacturing)

Cadence monthly

Why it matters Directly measures manufacturer-level price realizations and input inflation for electromedical and neurostimulation devices (TMS consoles, implantable pulse generators, leads), signaling pricing power and gross margin pressure.

Signal to watch Steady index gains indicate device makers can defend ASPs and pass on production costs to health systems, whereas flat or falling readings signal purchasing pushback.

Confidence: high

2. U.S. Census Bureau / FRED — Manufacturers' Shipments, Inventories, and Orders (M3) Survey

Matchedfred · access=api · map_only

Metric/field A34KVS (Electromedical, Measuring, and Control Instrument Manufacturing: Value of Shipments)

Cadence monthly

Why it matters Serves as a macro top-line benchmark for domestic shipments of advanced electrotherapeutic hardware ahead of quarterly earnings reports across MedTech suppliers.

Signal to watch Sequential shipment acceleration indicates robust hardware placement and capital installation cycles across hospital networks and outpatient centers.

Confidence: high

3. U.S. Bureau of Labor Statistics / FRED — Producer Price Index by Commodity

Matchedfred · access=api · map_only

Metric/field WPU511104 (Hospital Outpatient Care)

Cadence monthly

Why it matters Transcranial Magnetic Stimulation (STIM) and routine neurostimulator replacements are performed in outpatient settings; facility reimbursement rates dictate provider margin willingness to offer device therapies.

Signal to watch Expansion in outpatient service pricing reflects supportive payer reimbursement capture, enhancing provider appetite to invest in specialized neurotech suites.

Confidence: high

4. U.S. Bureau of Labor Statistics / FRED — Consumer Price Index for All Urban Consumers

Matchedfred · access=api · map_only

Metric/field CUSR0000SEMD (Hospital and Related Services in U.S. City Average)

Cadence monthly

Why it matters Tracks broad hospital procedural costs and operating capacity, highlighting hospital margin health and potential capex constraints that could delay elective neurosurgery device rollouts.

Signal to watch Stable price inflation alongside healthy hospital operating margins supports adoption of novel neurotech implants like CVRX Barostim and NPCE RNS.

Confidence: medium

5. U.S. Census Bureau / USITC — USA Trade Online

Not in registryaccess=api

Metric/field HTS 9021.90.8100 (Implantable Sacral and Other Neurostimulators Compensating for Defect or Disability)

Cadence monthly

Why it matters Measures cross-border trade flow, import volumes, and export values of finished neuromodulation devices and sub-assemblies, providing an early gauge of physical product demand and inventory replenishment.

Signal to watch Sustained increases in declared trade value and unit volumes indicate healthy commercial demand and supply-chain normalization for neuro devices.

Confidence: medium

Free Alt Data Watch

1. U.S. Food and Drug Administration (FDA CDRH) — OpenFDA Device PMA & 510(k) Database

Not in registry

Metric/field openfda.device_pma.decision_date (Product Codes: OLX, GZB, GXZ, LFO)

Cadence weekly

Why it matters Tracks regulatory velocity and approvals for next-generation TMS coils, closed-loop responsive neurostimulation systems, and baroreflex activation therapy under pro-innovation FDA frameworks.

Signal to watch Accelerated clearance rates and expanded indications (e.g., adolescent depression, focal and generalized epilepsy) signal addressable market expansion.

Confidence: high

2. National Institutes of Health (NIH) / NLM — ClinicalTrials.gov REST API v2

Not in registry

Metric/field protocolSection.statusModule.overallStatus (Conditions: 'Depression', 'Epilepsy', 'Heart Failure'; Interventions: 'TMS', 'Neurostimulation', 'Barostim', 'RNS')

Cadence monthly

Why it matters Monitors clinical trial progression, patient enrollment completion rates, and phase transitions for non-pharmaceutical neuro therapies across core basket indications.

Signal to watch A net increase in actively recruiting or completed pivotal trials validates clinical efficacy pipelines needed for broad commercial payer coverage.

Confidence: high

3. Centers for Medicare & Medicaid Services (CMS) — Medicare Coverage Database (MCD)

Not in registry

Metric/field Coverage_Indications_and_Limitations (CPT Codes: 90867, 90868, 61860, 61885, 0266T)

Cadence event_driven

Why it matters Monitors regional Medicare Administrative Contractor (MAC) Local Coverage Determinations (LCDs) and prior authorization criteria for TMS, RNS, and carotid sinus stimulation.

Signal to watch Shifts from non-coverage or onerous prior-authorization requirements to standardized affirmative LCDs remove commercial bottlenecks for device adoption.

Confidence: high

4. Centers for Medicare & Medicaid Services (CMS) — Hospital Outpatient Prospective Payment System (OPPS) Addendum B

Not in registry

Metric/field APC_Payment_Rate (APC 5462 [Level 2 Neurostimulator Implantation] and APC 5464 [Level 4 Neurostimulator Implantation])

Cadence quarterly

Why it matters Determines hospital outpatient and ambulatory surgery center (ASC) facility payments for neurostimulator insertions and generator exchanges, directly driving institutional profit margins.

Signal to watch Upward adjustments in APC reimbursement exceeding hospital input cost growth encourage Value Analysis Committees (VACs) to clear neurodevice adoption.

Confidence: high

5. U.S. Securities and Exchange Commission (SEC) — EDGAR Full-Text Filings & Company Facts API

Not in registry

Metric/field us-gaap:Revenues (CIKs: 0001550514 [CVRX], 0001227654 [STIM], 0001528287 [NPCE])

Cadence quarterly

Why it matters Tracks fundamental commercial execution, active hospital/clinic implant center additions, system utilization rates, and cash runway across the primary basket constituents.

Signal to watch Consecutive quarters of active center additions and recurring utilization revenue growth indicate successful commercial execution and operating leverage.

Confidence: high

Paid Alt Data Watch

1. IQVIA — PharMetrics Plus Longitudinal Medical Claims

Matchediqvia_medical_claims · access=file · map_only

Metric/field CPT_Procedure_Code_Volume (CPT 90867/90868 [TMS], 0266T/0267T [Barostim], 61860/61885 [RNS])

Cadence irregular

Why it matters Provides high-fidelity, near-real-time visibility into procedural billing volume, patient treatment continuity, and session completion rates across commercial and government health plans.

Signal to watch Sustained month-over-month increases in target procedure codes indicate expanding clinical uptake and procedural revenue momentum ahead of reported earnings.

Confidence: high

2. Definitive Healthcare — HospitalView & ProviderView Intelligence

Not in registry

Metric/field Facility_Purchase_Orders_Neurotech_Implant_Volume & Active_NPI_Prescribers

Cadence monthly

Why it matters Monitors hospital Value Analysis Committee (VAC) approval pipelines, device purchase orders, and active implanting physician counts across acute care and academic medical centers.

Signal to watch Broadening active prescriber counts and shorter VAC evaluation windows signal neurotech adoption moving from niche academic settings into regional community hospitals.

Confidence: high

3. Milliman / Komodo Health — Komodo Healthcare Map / Milliman HealthIO

Not in registry

Metric/field Medicare_Advantage_Encounter_Volume & Claim_Denial_Rate (Specialties: Neurology, Cardiology, Psychiatry)

Cadence monthly

Why it matters Assesses Medicare Advantage (MA) plan coverage friction, prior-authorization denial frequency, and encounter volume growth in line with administration policy support for non-drug neuro treatments.

Signal to watch Falling initial claim denial rates and rising MA encounter volumes confirm policy tailwinds are translating into realized cash reimbursement.

Confidence: medium

4. Earnest Analytics / Bloomberg Second Measure — Healthcare B2B Transaction Analytics

Matched (medium)bloomberg_second_measure_consumer_cohort_retention_analytics · access=file · map_only

Metric/field Neuro_Psych_Clinic_Spend_Index & Equipment_Lease_Transaction_Volume

Cadence irregular

Why it matters Measures accounts payable flows and equipment financing lease transaction activity across private psychiatric practices and specialty neurology clinics deploying capital hardware.

Signal to watch Rising transaction frequency and lease volume confirm clinic-level capital investment in neurotherapy systems and expanding patient treatment capacity.

Confidence: medium

5. AlphaSense / Tegus — Expert Network Stream Quantitative Intelligence

Matched (medium)alphasense_expert_interview_content · access=file · map_only

Metric/field KOL_Sentiment_Score & Mentions ('Barostim', 'NeuroStar', 'RNS System', 'Sacral Neuromodulation')

Cadence irregular

Why it matters Tracks quantitative and qualitative sentiment from key opinion leader (KOL) neurologists, psychiatrists, electrophysiologists, and hospital procurement directors.

Signal to watch Inflection from guarded trial adoption to enthusiastic first-line therapy recommendation signals accelerating real-world clinical acceptance.

Confidence: medium

Prediction Market Watch

Theme Plain English
This theme captures medical technology companies commercializing targeted neurostimulation and bioelectronic devices that treat chronic cardiovascular, psychiatric, and neurological disorders without relying on pharmaceuticals. Driven by policy tailwinds favoring non-drug therapies, expanded Medicare Advantage coverage, and accelerated FDA breakthrough pathways like RAPID, these device makers benefit as hospitals and outpatient clinics adopt bioelectronic implants and non-invasive neuromodulation systems as frontline standards of care.
Key Metrics3 rows
MetricCadenceWhat It SignalsUpdate Source
FDA breakthrough and device approval activityMonthlyMeasures regulatory velocity for novel neurotechnologies (e.g., TMS, nerve repair).Google_Sheets
Medicare Advantage neuroprocedure volumesQuarterlyIndicates coverage-driven demand trends for devices like CVRX, NPCE, and STIM.Google_Sheets
Hospital procedure adoption and CPT reimbursement ratesQuarterlyReflects clinical uptake and payer willingness to support neuromodulation therapies.Google_Sheets
Upcoming Catalysts6 rows
Catalyst IDEstimated TimingEstimated Date StartEstimated Date EndCatalystWhy It MattersTicker Or Theme SpecificTranscript DateSource TypeCatalyst Source
ABT_79370e41in the fall2026-09-012026-11-30Potential Medicare coverage expansion for Libre Continuous Glucose Monitoring (CGM) for Type 2 non-insulin users in the US.This could unlock a multibillion-dollar opportunity by accelerating commercial insurance coverage and reaching approximately 10 million Medicare beneficiaries, significantly boosting CGM sales.Ticker2026-07-16earnings_transcriptABT (ticker)
ABT_30e24e43by year-end 20262026-10-012026-12-31FDA approval and US launch of Amulet 360 Left Atrial Appendage (LAA) device.This device is designed to help reduce the risk of stroke in patients with AFib and is expected to reignite growth and capture market share in the LAA closure market.Ticker2026-10-21earnings_transcriptABT (ticker)
ABT_7cc559f2starting in the fourth quarter2026-10-012026-12-31Broad U.S. launch of TactiFlex Duo catheter.This catheter enables physicians to seamlessly switch between using RF and PFA energy during a procedure, which is expected to drive adoption and market share in electrophysiology.Ticker2026-10-21earnings_transcriptABT (ticker)
ABT_8bb43b0esometime in Q42026-10-012026-12-31Launch of Volt PFA catheter in Japan.This launch is expected to turn Japan from a headwind to a tailwind for the electrophysiology business, contributing to international growth acceleration.Ticker2026-10-21earnings_transcriptABT (ticker)
ABT_6009f906in December2026-12-012026-12-31U.S. launch of Libre Duo, the world's first dual glucose ketone biowearable sensor.This product allows people with diabetes to monitor ketones without traditional blood or urine tests, offering a new growth driver for the diabetes care business.Ticker2026-10-21earnings_transcriptABT (ticker)
ABT_c375ff52January 12027-01-012027-01-01Significant U.S. payer formulary coverage for Libre goes into effect.This expanded coverage is expected to be a nice growth driver for the diabetes business in the coming year.Ticker2026-10-21earnings_transcriptABT (ticker)

Loading correlation…

Constituents

  • ABTT3
    — Abbott Laboratories
  • — Globus Medical, Inc.
  • BSXT3
    · no notes yet
  • BWAYT3
    · no notes yet
  • CVRXT3
    · no notes yet
  • INSPT3
    · no notes yet
  • LIVNT3
    · no notes yet
  • MDTT3
    · no notes yet
  • NPCET3
    · no notes yet
  • NYXHT3
    · no notes yet
  • OBIOT3
    · no notes yet
  • SLD.AUT3
    · no notes yet
  • STIMT3
    · no notes yet